scholarly journals Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine.

1992 ◽  
Vol 89 (5) ◽  
pp. 1934-1938 ◽  
Author(s):  
P. Kellam ◽  
C. A. Boucher ◽  
B. A. Larder
2000 ◽  
Vol 74 (2) ◽  
pp. 1023-1028 ◽  
Author(s):  
Tomozumi Imamichi ◽  
Tanima Sinha ◽  
Hiromi Imamichi ◽  
Yi-Ming Zhang ◽  
Julie A. Metcalf ◽  
...  

ABSTRACT A variant of human immunodeficiency virus type 1 (HIV-1) possessing a deletion in the reverse transcriptase (RT) gene at codon 67 was identified in a patient who had failed combination antiretroviral therapy. This deletion initially emerged under the selective pressure of combination therapy with 3′-azido-3′-deoxythymidine (AZT) plus 2′,3′-dideoxyinosine. It has persisted for more than 3 years in association with the accumulation of a variety of other well-described drug resistance mutations and an uncharacterized mutation at RT codon 69 (T69G). Phenotypic studies demonstrated that the codon 67 deletion by itself had little effect on AZT sensitivity. However, in the context of the T69G mutation and three other mutations known to be associated with AZT resistance (K70R, T215F, and K219Q), this deletion led to a increase in AZT resistance from 8.5-fold to 445-fold. A further increase in resistance (up to 1,813-fold) was observed when two mutations associated with nonnucleoside RT inhibitor resistance (K103N and L74I) were added to the deletion T69G K70R T215F K219Q construct. Hence, these results establish that a deletion at RT codon 67 may be selected for in the presence of antiretroviral therapy and may lead to high-level resistance to AZT.


1999 ◽  
Vol 43 (8) ◽  
pp. 2077-2080 ◽  
Author(s):  
Robert A. Smith ◽  
George J. Klarmann ◽  
Kirsten M. Stray ◽  
Uta K. von Schwedler ◽  
Raymond F. Schinazi ◽  
...  

ABSTRACT A P157S mutation in the reverse transcriptase (RT) of human immunodeficiency virus type 1 conferred fivefold resistance to (−)-β-2′,3′-dideoxy-3′-thiacytidine in cell culture. Interestingly, the P157S mutation resulted in increased sensitivity (two- to threefold) to 3′-azido-3′-deoxythymidine (AZT) and to (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA). A similar increase in susceptibility to AZT and to PMPA was also conferred by the M184V mutation in RT.


2000 ◽  
Vol 74 (8) ◽  
pp. 3579-3585 ◽  
Author(s):  
Matthias Götte ◽  
Dominique Arion ◽  
Michael A. Parniak ◽  
Mark A. Wainberg

ABSTRACT Nucleoside analog chain terminators such as 3′-azido-3′-deoxythymidine (AZT) and 2′,3′-dideoxy-3′-thiacytidine (3TC) represent an important class of drugs that are used in the clinic to inhibit the reverse transcriptase (RT) of human immunodeficiency virus type 1. Recent data have suggested that mutant enzymes associated with AZT resistance are capable of removing the chain-terminating residue with much greater efficiency than wild-type RT and this may, in turn, facilitate rescue of DNA synthesis; these experiments were performed using physiological concentrations of pyrophosphate or nucleoside triphosphates, respectively. The present study demonstrates that the M184V mutation, which confers high-level resistance to 3TC, can severely compromise the removal of chain-terminating nucleotides. Pyrophosphorolysis on 3TC-terminated primer strands was not detectable with M184V-containing, as opposed to wild-type, RT, and rescue of AZT-terminated DNA synthesis was significantly decreased with the former enzyme. Thus, mutated RTs associated with resistance to AZT and 3TC possess opposing, and therefore incompatible, phenotypes in this regard. These results are consistent with tissue culture and clinical data showing sustained antiviral effects of AZT in the context of viruses that contain the M184V mutation in the RT-encoding gene.


Sign in / Sign up

Export Citation Format

Share Document